Publications dans lesquelles il/elle collabore avec Daniel Ajona Martínez-Polo (41)

2024

  1. Fasting and fasting-mimicking conditions in the cancer immunotherapy era

    Journal of Physiology and Biochemistry

  2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells

    Cancer Letters, Vol. 549

  3. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

  4. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients

    Cytokine, Vol. 141

  3. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  4. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

  5. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  6. The complement system in ovarian cancer: An underexplored old path

    Cancers, Vol. 13, Núm. 15

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  2. Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment

    Seminars in Cell and Developmental Biology, Vol. 85, pp. 153-163

  3. Complement in metastasis: A comp in the camp

    Frontiers in Immunology, Vol. 10, Núm. APR

  4. Complementing the cancer-immunity cycle

    Frontiers in Immunology, Vol. 10, Núm. APR

  5. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery

    Cancer Letters, Vol. 453, pp. 21-33